CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25770292.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2551 and PMC identifier 4362690.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a landmark article published in the May 1, 2001, issue of Clinical Cancer Research, Lee and colleagues reported the original preclinical studies demonstrating anticancer activity of BMS-247550 (ixabepilone) against taxane-sensitive and taxane-resistant cancers. Subsequent clinical trials established the clinical efficacy of ixabepilone, leading to its regulatory approval for the treatment of drug-resistant metastatic or locally advanced breast cancers.
Medical subject headings
- Antineoplastic Agents
- Breast Neoplasms
- Epothilones
- Microtubules
- Tubulin Modulators